AstraZeneca’s COVID-19 vaccine rollout has gotten off to a rocky start in Europe. First, a supply shortfall triggered a public back-and-forth between executives and government officials. Then, several countries raised efficacy doubts for people over 65. Now some countries are raising safety concerns.